Last updated: May 26, 2026
Suppliers for Lupron Depot (leuprolide acetate): Who Manufactures the Drug Product, Solvent Systems, and Key Raw Materials?
Lupron Depot is a branded depot formulation of leuprolide acetate (a GnRH agonist) marketed by AbbVie (via its predecessor Allergan) in the US. The supply chain for the depot is split across (1) drug substance leuprolide acetate and (2) drug product manufacturing that packages the controlled, sterile depot platform (lyophilized/rehydration and depot assembly depending on strength and kit format). Exact contract manufacturers and individual supplier names for each component are not consistently disclosed in public FDA and Orange Book records. What is publicly determinable is the regulatory linkage: the FDA application lists the approved manufacturer(s), labelers, and submission holders for each strength, and those entities anchor supplier selection for procurement, CMOs, and technical transfer.
Who supplies Lupron Depot in FDA records: application holders, labelers, and manufacturing sites?
Short answer: In US regulatory records, the primary supply-relevant entities are the drug product “applicant/labeler” and the drug product manufacturing site(s) tied to the approved NDA/BLA listing for each Lupron Depot strength.
What FDA listing fields typically identify for supplier mapping
For each Lupron Depot strength, FDA labeling and submission metadata (captured in Orange Book and FDA product details) typically supports mapping to:
- Application/holder (the legal entity responsible for the NDA listing and label)
- Labeler (market authorization and distribution entity)
- Drug product manufacturer(s) (site(s that release drug product)
- Drug substance manufacturer(s) are not always populated at the same level of detail publicly for every NDA strength, but some are reflected in labeling and manufacturing descriptions.
Orange Book status: is Lupron Depot listed and what does that imply for suppliers?
If a product is listed in the Orange Book with a reference listed drug (RLD), it implies a legally recognized approved drug product and a stable manufacturing/labeler record that procurement groups use for supplier qualification.
Which drug product manufacturers make Lupron Depot for each strength?
Short answer: Drug product manufacturing is strength-specific. Each strength can map to different approved manufacturing sites, especially where manufacturing changes have been filed via prior approval supplements.
Strength-by-strength approach used by procurement
Supplier diligence for Lupron Depot is typically executed by strength (for example, multi-month depots), then by:
- NDA strength name and presentation
- Listed manufacturer site on FDA label
- Compatibility with the depot platform (sterile manufacturing environment, aseptic processing controls, and kit assembly)
What to look for in supplier due diligence dossiers
For depot injectables like Lupron Depot, supplier qualification generally focuses on:
- Sterile manufacturing compliance (aseptic processing and terminal sterilization method if applicable)
- Sterility assurance controls and container closure integrity for kits
- Particle size and viscosity controls that affect depot uniformity
- Stability and reconstitution performance across shelf life
- NDA-conformance for leuprolide acetate crystallinity and impurity profile (drug substance influence)
What supplies leuprolide acetate drug substance for Lupron Depot?
Short answer: Leuprolide acetate drug substance supplier identification is often constrained in public sources; however, regulator-facing records tie the drug product to an approved manufacturing route and impurity specification that only qualified upstream vendors can meet.
How drug substance supplier selection works for GnRH depot APIs
Drug substance procurement for leuprolide acetate is typically governed by:
- Impurity profile controls aligned with the NDA specification
- Particle size distribution that affects suspension/reconstitution and depot consistency
- Polymorph/crystallinity constraints for stability in depot formulations
- Validated synthesis route capacity and regulatory audit outcomes
What evidence typically exists publicly
Public disclosures that can be used in supplier mapping include:
- NDA chemistry/manufacturing descriptions embedded in the FDA package (not always indexed in a way that yields a simple supplier name list)
- Labeling references to “manufactured for” and corporate entities tied to the NDA holder and drug product site
What sterile manufacturing systems and components are typically sourced for Lupron Depot kits?
Short answer: Depot injectables require a tightly controlled supply of sterile and kit components: prefilled/supplied delivery components, sterile diluent or reconstitution components, and container closure systems that meet depot compatibility requirements.
Kit-level supplier categories
Procurement due diligence for Lupron Depot-style depots usually includes:
- Sterile diluent or reconstitution solvent supplied as a kit component (platform-specific)
- Sterile vials/syringes and stoppers compatible with the formulation
- Injection needle and transfer components used in administration
- Aseptic packaging supplies and secondary cartons
Why kit suppliers matter for depot products
Depot uniformity depends on:
- Reconstitution completeness and suspension quality
- Container materials that do not leach or adsorb drug
- Closure integrity that prevents particulate ingress and moisture changes
Are there multiple suppliers for Lupron Depot to ensure continuity?
Short answer: Large depot injectables commonly maintain multiple qualified manufacturing sites and raw material sources, but the public record often does not list every alternative supplier. What can be stated from a compliance perspective is that supply continuity requires redundancy in at least the drug product release and critical component procurement.
Typical redundancy layers used for depot injectables
- Drug product release site redundancy (different manufacturing sites releasing finished sterile product)
- Batch release redundancy for drug substance (qualified API vendors)
- Critical component qualified supplier programs (closures, vials, diluents)
- Change control and comparability packages for post-approval manufacturing updates
What suppliers support regulatory and manufacturing compliance for Lupron Depot?
Short answer: The entities that matter for regulatory and litigation readiness are the NDA holder/applicant and the drug product manufacturer(s) listed on FDA records. These parties anchor:
- Current Good Manufacturing Practice (cGMP) compliance
- Validation of manufacturing processes
- Stability and comparability for lifecycle management
- Quality management system readiness for FDA inspections
How procurement teams validate supplier readiness
- Audit reports for sterile manufacturing controls
- Batch record traceability and deviation management
- Analytical method validation for leuprolide acetate identity, assay, and impurities
- Stability data packages covering temperature excursions and shipping
How does the supplier ecosystem differ for Lupron Depot vs other leuprolide depot brands?
Short answer: Supplier ecosystems vary by dosage form, depot matrix, and kit configuration, even when the active pharmaceutical ingredient is the same. Depot platform differences drive different sterile manufacturing steps, container closure requirements, and reconstitution performance specifications.
Comparative procurement considerations for GnRH depot products
- Different depot matrices and particle size targets
- Different injection kits and reconstitution workflows
- Different sterilization approach constraints and container compatibility
- Different lifecycle change histories across brands and generics
Key Takeaways
- Lupron Depot’s supplier map in public FDA records centers on the NDA holder/applicant and the listed drug product manufacturer(s) by strength; those are the key procurement and compliance anchor points.
- Leuprolide acetate drug substance supply is constrained by impurity and physical property specifications that downstream sterile depot performance depends on.
- Depot injectables require tightly controlled supply of sterile kit components including diluent/solvent and container closure systems; kit supplier qualification is integral to product performance and regulatory defensibility.
- Supply continuity typically relies on redundancy in drug product release and upstream API or critical component qualification, but publicly available sources do not consistently enumerate every alternative supplier name.
FAQs
Which entities are listed as the manufacturer for Lupron Depot on FDA labeling?
FDA labeling and Orange Book-linked product information list specific drug product manufacturer entities by strength, which act as the authoritative anchors for supplier identification in regulatory procurement.
Can generics of leuprolide depot use the same suppliers as Lupron Depot?
Not automatically. Even when the API is the same, drug product formulation platform and kit configuration drive qualification requirements and can require different sterile manufacturing and critical component suppliers.
What components in Lupron Depot are most sensitive to supplier changes?
Sterile delivery components, reconstitution diluent/solvent kit items, and container closure systems are sensitive because they affect suspension quality, reconstitution completeness, and depot uniformity.
How do procurement teams qualify new suppliers for depot injectables?
They qualify via audit readiness, analytical capability for API and depot-specific critical quality attributes, validated sterile manufacturing controls, and stability/comparability evidence aligned with the NDA.
What supply risks are common for depot GnRH agonists?
Common risks include constrained sterile manufacturing capacity, long lead-time critical components (closures/vials/needles), and API supply disruptions driven by limited qualified upstream vendors meeting strict impurity and physical property specs.
References
- US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- US FDA. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/
